<DOC>
	<DOCNO>NCT00738764</DOCNO>
	<brief_summary>This phase 1 , multicenter , open-label , dose escalation trial PDL192 subject advanced solid tumor .</brief_summary>
	<brief_title>A Trial PDL192 Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description>The primary study objective determine maximum tolerate dose PDL192 subject advance solid tumor .</detailed_description>
	<criteria>Inclusion Criteria Eligible subject consider inclusion study meet follow criterion : 1 . Male female , 18 year age old . 2 . Subjects document advanced solid tumor . 3 . Subjects previously fail standard therapy subject tumor standard therapy exists . 4 . A negative serum pregnancy test ( woman childbearing potential ) screening . Male female subject reproductive potential must willing use adequate contraception duration study minimum 3 month end treatment . 5 . Ability understand purpose risk study provide sign date informed consent authorization use protect health information ( accordance national local subject privacy regulation ) . Exclusion Criteria Subjects ineligible study meet one follow criterion : 1 . Symptomatic progressive central nervous system ( CNS ) metastases leptomeningeal metastasis 2 . Diagnosis glioblastoma 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; = 2 4 . Abnormal hematologic value define : Hemoglobin level &lt; 9 g/dL Absolute neutrophil count ( ANC ) &lt; 1500/mm3 Platelet count &lt; 100,000/mm3 5 . Abnormal kidney , liver , pancreatic function define : Serum creatinine &gt; 1.5 x upper limit normal value ( ULN ) Aspartate transaminase alanine transaminase level &gt; = 2.5 x ULN Bilirubin &gt; ULN Amylase &gt; 1.5 x ULN Lipase &gt; 1.5 x ULN 6 . Known chronic viral hepatitis 7 . History cirrhotic liver disease 8 . History pancreatitis ( patient history gall stone pancreatitis status postcholecystectomy eligible ) 9 . Acute cholecystitis within 6 month prior first dose study drug 10 . Treatment investigational drug , antineoplastic agent , antibody within 21 day prior first dose study drug ( 6 week vaccine nitrosureas ) 11 . Proteinuria &gt; 1 g/24 hour ( subject &gt; = 2+ dipstick test undergo 24 hour urine collection ) 12 . Ongoing &gt; = Grade 2 toxicity result prior therapy 13 . Received continuous systemic steroid dos great 10 mg/day prednisone equivalent within 30 day prior first dose study drug ( intermittent dexamethasone give prophylaxis treatment emesis permit ) 14 . Received immunosuppressive agent ( except steroid ) within 21 day prior first dose study drug 15 . Known hypersensitivity component PDL192 formulation 16 . Uncontrolled medical problem diabetes mellitus , pancreatitis , coronary artery disease , hypertension , unstable angina , arrhythmia , pulmonary disease , symptomatic heart failure 17 . Female subject pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>cancer</keyword>
	<keyword>antibody</keyword>
	<keyword>Phase 1 Clinical Trial</keyword>
</DOC>